Supplementary Figure from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Hiatt, Joseph; Sandborg, Holly; Garrison, Sarah M.; Arnold, Henry U.; Liao, Sheng-You; Norton, Justin P.; Friesen, Travis J.; Wu, Feinan; Sutherland, Kate D.; Rienhoff, Hugh Y.; Martins, Renato; Houghton, A. McGarry; Srivastava, Shivani; MacPherson, David

doi:10.1158/1078-0432.22488479.v1

2023

DOI: 10.1158/1078-0432.22488479.v1

|View full text |Cite

Preprint

Supplementary Figure from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Joseph Hiatt¹,

Holly Sandborg²,

Sarah M. Garrison³

et al.

Abstract: Supplementary Figure from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Help me understand this report

View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Mamun,

Zhang,

Zhao

et al. 2023

J Biomed Sci

View full text Add to dashboard Cite

Dysregulation of various cells in the tumor microenvironment (TME) causes immunosuppressive functions and aggressive tumor growth. In combination with immune checkpoint blockade (ICB), epigenetic modification-targeted drugs are emerging as attractive cancer treatments. Lysine-specific demethylase 1 (LSD1) is a protein that modifies histone and non-histone proteins and is known to influence a wide variety of physiological processes. The dysfunction of LSD1 contributes to poor prognosis, poor patient survival, drug resistance, immunosuppression, etc., making it a potential epigenetic target for cancer therapy. This review examines how LSD1 modulates different cell behavior in TME and emphasizes the potential use of LSD1 inhibitors in combination with ICB therapy for future cancer research studies.

show abstract

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Mamun,

Zhang,

Zhao

et al. 2023

J Biomed Sci

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Supplementary Figure from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Abstract: Supplementary Figure from Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing

Cited by 1 publication

References 0 publications

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy

Contact Info

Product

Resources

About